Celcuity Inc. (CELC)

Celcuity's stock price has been impacted by several key events. The FDA accepted Celcuity's New Drug Application for gedatolisib, granting it Priority Review, which led to a stock gain. Positive data from the Phase 3 VIKTORIA-1 trial was published, highlighting the drug's efficacy. Investor optimism was fueled by the anticipation of topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 trial. Wall Street analysts have maintained a bullish outlook on Celcuity, with elevated price targets. Celcuity reported its Q4 and full-year 2025 financial results, reaffirming having enough cash to fund operations through 2027. Celcuity announced a new public stock offering, which caused the shares to tumble due to dilution.

Celcuity, Inc.'s products and services do not exhibit traditional demand seasonality. The company's revenue generation is primarily tied to the successful development, regulatory approval, and future commercialization of its drug candidates and diagnostic tests. Key drivers for the company's financial performance are clinical trial outcomes, FDA decisions, and potential licensing or commercialization agreements.

Celcuity, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for solid tumor indications, particularly in oncology. Their core business involves discovering new cancer sub-types and commercializing diagnostic tests to improve clinical outcomes for cancer patients receiving targeted therapies. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor, being developed for various cancers. Celcuity also utilizes its proprietary CELsignia diagnostic platform to identify specific abnormal cellular processes driving a patient's cancer.

Celcuity, Inc. is headquartered in Minneapolis, Minnesota, United States. The company's primary focus for developing therapies is in the United States, with a strategic goal to expand geographically to tap into larger global patient populations and generate additional revenue streams.

Celcuity's brand reputation appears to be largely positive, particularly within the financial and biotechnology communities. The company has received strong analyst sentiment and elevated price targets. The significant increase in its stock price reflects a positive market perception and investor confidence, driven by promising clinical trial results and regulatory milestones for gedatolisib. No specific events negatively impacted Celcuity's brand reputation.

Celcuity Inc. has significant institutional ownership, with 249 institutional owners and shareholders holding a total of 47,920,353 shares as of April 8, 2026. Major institutional owners include Baker Bros. Advisors Lp, NEA Management Company, LLC, and Perceptive Advisors Llc. Key individual insiders and major shareholders include Felix Baker, Brian F. Sullivan, and Lance G. Laing.